Log In
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?
Log In
Don't have an account? Sign Up Here
Join Us
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
I agree to TheMaven's
Terms
and
Policy
Sign Up
Already have an account? Login here
JIM CRAMER
INVESTING
PERSONAL FINANCE
RETIREMENT
TECHNOLOGY
MARKETS
HOW-TO
VIDEO
FINANCIAL ADVISOR CENTER
Search
Trade with Jim Cramer 14 Days Free
Join the Action Alerts PLUS Community today!
SUBSCRIBE NOW
LATEST NEWS
STOCKS
What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
By Adam Feuerstein
Dec 22, 2016 11:20 AM EST
PRESS RELEASES
Ampio Provides Update On Clinical Trials For Ampion™ Treatment Of COVID-19 Patients
By PR Newswire
Jan 4, 2021 9:15 AM EST
PRESS RELEASES
Ampio Receives Feedback From The FDA On Ampio's Proposed Modifications To The Special Protocol Assessment For Ampion Treatment Of Severe Osteoarthritis Of The Knee
By PR Newswire
Dec 29, 2020 9:15 AM EST
PRESS RELEASES
Ampion Demonstrates Safety In COVID-19 Patients And Initiates Global Clinical Trial For Intravenous Ampion
By PR Newswire
Dec 17, 2020 9:15 AM EST
PRESS RELEASES
Ampio Enters Into Collaborative Research Agreements To Explore Additional Clinical Indications For Its Immunomodulatory Drug, Ampion
By PR Newswire
Dec 10, 2020 9:15 AM EST
PRESS RELEASES
Ampio Pharmaceuticals, Inc. To Host Its Annual Meeting On December 12, 2020
By PR Newswire
Dec 8, 2020 9:15 AM EST
PRESS RELEASES
Ampio's Phase I Study For Inhaled Ampion Advances To Completing Enrollment Of COVID-19 Patients With Respiratory Distress
By PR Newswire
Dec 2, 2020 9:15 AM EST
PRESS RELEASES
Ampio Updates Regulatory And Clinical Trial Events
By PR Newswire
Nov 25, 2020 9:15 AM EST
PRESS RELEASES
Ampio's Phase I Study For Inhaled Ampion Advances To 3rd Group Of COVID-19 Patients With Respiratory Distress
By PR Newswire
Nov 17, 2020 9:15 AM EST
PRESS RELEASES
Ampio's Phase I Study For Inhaled Ampion Advances To 2nd Group Of COVID-19 Patients With Respiratory Distress
By PR Newswire
Nov 10, 2020 4:01 PM EST
PRESS RELEASES
Ampio Pharmaceuticals, Inc. Provides Business Update And Reports Third Quarter 2020 Financial Results
By PR Newswire
Nov 5, 2020 3:45 PM EST
PRESS RELEASES
Ampio Pharmaceuticals, Inc. To Host Conference Call On November 5th
By PR Newswire
Nov 2, 2020 9:15 AM EST
PRESS RELEASES
Ampio Begins Phase 1 Clinical Trial Of Inhaled Ampion For COVID-19 Patients With Respiratory Distress
By PR Newswire
Oct 28, 2020 7:30 AM EDT
PRESS RELEASES
Ampio Pharmaceuticals, Inc. To Present At The ROTH Capital Healthcare Event "COVID-19 Therapeutics In Development"
By PR Newswire
Oct 27, 2020 9:15 AM EDT
PRESS RELEASES
Ampio Presents At Roth Capital Partners 2020 MedTech Innovation Forum Focusing On COVID-19 Clinical Trial Activities
By PR Newswire
Oct 26, 2020 9:15 AM EDT
PRESS RELEASES
Ampion Phase I COVID-19 Patient Trial Results Featured On FOX News (Video)
By PR Newswire
Sep 14, 2020 9:15 AM EDT
PRESS RELEASES
Ampio Reports Positive Results For Ampion Treatment In COVID-19 Patients
By PR Newswire
Sep 9, 2020 9:15 AM EDT
PRESS RELEASES
Ampio Announces Enrollment Completion For Intravenous ("IV") COVID-19 Clinical Trial & Provides Update On Osteoarthritis Of The Knee ("OAK") Clinical Trial
By PR Newswire
Sep 4, 2020 9:15 AM EDT
PRESS RELEASES
Ampio Provides Update On COVID-19 Clinical Trial Activities
By PR Newswire
Aug 19, 2020 8:00 AM EDT
PRESS RELEASES
Ampio Starts Patient Enrollment In Its Ampion COVID-19 Program
By PR Newswire
Jul 23, 2020 8:00 AM EDT
PRESS RELEASES
Ampio Reports A Publication On The Potential Benefits Of Ampion For Treatment Of A New COVID-19 Related Syndrome
By PR Newswire
Jul 20, 2020 8:00 AM EDT
PRESS RELEASES
Ampio To Start First Clinical Trial In COVID-19 Program
By PR Newswire
Jun 19, 2020 8:00 AM EDT
PRESS RELEASES
Ampio Provides Update On COVID-19 Program
By PR Newswire
May 22, 2020 8:00 AM EDT
PRESS RELEASES
Ampio Reports Acceptance Of Publication On The Potential Benefits Of Nebulized Ampion™ For COVID-19 Patients
By PR Newswire
May 11, 2020 8:00 AM EDT
PRESS RELEASES
Ampio Pharmaceutical's Application To The FDA For A Clinical Study Of Ampion™ To Treat COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS) Featured In FOX News (VIDEO)
By PR Newswire
Apr 2, 2020 9:00 AM EDT